# EDGAR Filing Document

**Accession Number:** 0001662244
**File Stem:** 0000950170-23-009504
**Filing Date:** 2023-3
**Character Count:** 15048
**Document Hash:** 0890034bd36718fd3be3563fc6afbf1a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-009504.hdr.sgml**: 20230323

**ACCESSION NUMBER**: 0000950170-23-009504

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20230323

**DATE AS OF CHANGE**: 20230323

**EFFECTIVENESS DATE**: 20230323

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cyteir Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001662244
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 455429901
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270787
- **FILM NUMBER:** 23756484

**BUSINESS ADDRESS:**
- **STREET 1:** 128 SPRING STREET
- **STREET 2:** BUILDING A, SUITE 510
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421
- **BUSINESS PHONE:** 857-285-4140

**MAIL ADDRESS:**
- **STREET 1:** 128 SPRING STREET
- **STREET 2:** BUILDING A, SUITE 510
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421

**As filed with the Securities and Exchange Commission on March 23, 2023** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, DC 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

**UNDER** 

**THE SECURITIES ACT OF 1933** 

**CYTEIR THERAPEUTICS, INC.** 

**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **45-5429901** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification No.)** |
| **128 Spring St, Building A, Suite 510, Lexington, MA** | **02421** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Cyteir Therapeutics, Inc. 2021 Equity Incentive Plan** 

**Cyteir Therapeutics, Inc. 2021 Employee Stock Purchase Plan**

**(Full titles of the plans)** 

**Markus Renschler, M.D.** 

**President and Chief Executive Officer** 

**Cyteir Therapeutics, Inc.** 

**128 Spring St, Building A, Suite 510** 

**Lexington, MA 02421** 

**(Name and address of agent for service)** 

**(857) 285-4140** 

**(Telephone number, including area code, of agent for service)** 

**Please send copies of all communications to:** 

**Marc A. Rubenstein, Esq.** 

**Tara Fisher** 

**Ropes & Gray LLP** 

**Prudential Tower** 

**800 Boylston Street** 

**Boston, MA 02199-3600** 

**617-951-7000** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer, "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 registers additional shares of the Registrant's common stock, par value $0.001 per share (the "Common Stock"), under the Registrant's 2021 Equity Incentive Plan (the "2021 Plan") and the Registrant's 2021 Employee Stock Purchase Plan ("2021 ESPP").

The number of shares of Common Stock reserved and available for issuance under the 2021 Plan is subject to an automatic annual increase on January 1 of each year by an amount equal to lesser of (i) five (5) percent of the number of shares of Common Stock outstanding as of such date and (ii) the number of shares of Common Stock determined by the Board on or prior to such date for such year. On January 1, 2023, the number of shares of Common Stock reserved and available for issuance under the 2021 Plan increased by 1,778,784 shares.

The number of shares of Common Stock reserved and available for issuance under the 2021 ESPP is subject to an automatic annual increase on January 1 of each year by an amount equal to one (1) percent of the number of shares of Common Stock issued and outstanding as of such date or such lesser number of shares of Common Stock as determined by the Board of Directors. On January 1, 2023, the number of shares of Common Stock reserved and available for issuance under the 2021 ESPP increased by 355,756 shares.

This Registration Statement on Form S-8 registers these additional 2,134,540 shares of Common Stock. The additional shares are of the same class as other securities relating to the plans for which the Registrant's registration statement filed on Form S-8 (Registration No. 333-257920) on July 15, 2021 is effective. The information contained in the Registrant's registration statement on Form S-8 (Registration No. 333-257920) is hereby incorporated by reference pursuant to General Instruction E.

------

**PART II** 

**Item 8. Exhibits.** 

---

| | |
|:---|:---|
| **Exhibit** |  |
| 4.1 | [<u>Sixth Amended and Restated Certificate of Incorporation (previously filed as Exhibit 3.1 to the Current Report of Form 8-K filed on June 25, 2021 (File No. 001-40499) and incorporated herein by reference).</u>](https://www.sec.gov/Archives/edgar/data/0001662244/000119312521200594/d172725dex31.htm) |
| 4.2 | [<u>Second Amended and Restated Bylaws (previously filed as Exhibit 3.2 to the Current Report of Form 8-K filed on June 25, 2021 (File No. 001-40499) and incorporated herein by reference).</u>](https://www.sec.gov/Archives/edgar/data/0001662244/000119312521200594/d172725dex32.htm) |
| 4.3 | [<u>Cyteir Therapeutics, Inc. 2021 Equity Incentive Plan (previously filed as Exhibit 10.11 to the Registration Statement on Form S-1/A (File No. 333-256601) and incorporated herein by reference).</u>](https://www.sec.gov/Archives/edgar/data/0001662244/000119312521189385/d115570dex1011.htm) |
| 4.4 | [<u>Cyteir Therapeutics, Inc. 2021 Employee Stock Purchase Plan (previously filed as Exhibit 10.15 to the Registration Statement on Form S-1/A (File No. 333-256601) and incorporated herein by reference).</u>](https://www.sec.gov/Archives/edgar/data/1662244/000119312521189385/d115570dex1015.htm) |
| 5.1 | [<u>Opinion of Ropes & Gray LLP</u>](cyt-ex5_1.htm) |
| 23.1 | [<u>Consent of Ernst & Young LLP</u>](cyt-ex23_1.htm) |
| 23.2 | [<u>Consent of Ropes & Gray LLP (included in the opinion filed as Exhibit 5.1)</u>](cyt-ex5_1.htm) |
| 24.1 | [<u>Powers of Attorney (included on the signature page in Part II)</u>](#power_attorney) |
| 107 | [<u>Filing Fee Table</u>](cyt-exfiling_fees.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lexington, Commonwealth of Massachusetts, on this 23rd day of March, 2023.

---

| | |
|:---|:---|
| **CYTEIR THERAPEUTICS, INC.** | **CYTEIR THERAPEUTICS, INC.** |
| By: | /s/ Markus Renschler |
|  | Name: Markus Renschler, M.D. |
|  | Title: President and Chief Executive Officer |

---

**POWER OF ATTORNEY** 

Each person whose signature appears below constitutes and appoints Markus Renschler and Adam Veness, each of them acting singly, his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 to be filed by Cyteir Therapeutics, Inc., and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.

\* \* \* \*

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Markus Renschler, M.D.<br>Markus Renschler, M.D. | President, Chief Executive Officer and Director<br>(Principal Executive Officer) | March 23, 2023 |
| /s/ David Gaiero<br>David Gaiero | Chief Financial Officer<br>(Principal Accounting and Financial Officer) | March 23, 2023 |
| /s/ Racquel Bracken<br>Racquel Bracken | Director | March 23, 2023 |
| /s/ Jean George, M.B.A.<br>Jean George, M.B.A. | Director | March 23, 2023 |
| /s/ Jeffrey Humphrey, M.D.<br>Jeffrey Humphrey, M.D. | Director | March 23, 2023 |
| /s/ Susan Molineaux, Ph.D.<br>Susan Molineaux, Ph.D. | Director | March 23, 2023 |
| /s/ Timothy Romberger<br>Timothy Romberger | Director | March 23, 2023 |
| /s/ Stephen Sands<br>Stephen Sands | Director | March 23, 2023 |
| /s/ John Thero<br>John Thero | Director | March 23, 2023 |
| /s/ Joseph S. Zakrzewski<br>Joseph S. Zakrzewski | Director | March 23, 2023 |

---

------

## Ex-5

**Exhibit 5.1**

![img21563576_0.jpg](img21563576_0.jpg)

March 23, 2022

Cyteir Therapeutics, Inc.

128 Spring Street, Building A, Suite 510

Lexington, MA 02421

Ladies and Gentlemen:

This opinion letter is furnished to you in connection with the registration statement on Form S-8 (the "<u>Registration Statement</u>"), filed by Cyteir Therapeutics, Inc., a Delaware corporation (the "<u>Company</u>"), on the date hereof, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), for the registration of 2,134,540 shares of common stock, $0.001 par value per share, of the Company (the "<u>Shares</u>"). The Shares are issuable under the Company's 2021 Equity Incentive Plan and the Company's 2021 Employee Stock Purchase Plan (each, a "<u>Plan</u>" and collectively, the "<u>Plans</u>").

We are familiar with the actions taken by the Company in connection with the adoption of the Plans. We have examined such certificates, documents and records and have made such investigation of fact and such examination of law as we have deemed appropriate in order to enable us to render the opinions set forth herein. In conducting such investigation, we have relied, without independent verification, upon certificates of officers of the Company, public officials and other appropriate persons.

The opinions expressed below are limited to the Delaware General Corporation Law.

Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized and, when the Shares have been issued and sold in accordance with the terms of the applicable Plan, the Shares will be validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

Very truly yours,

/s/ Ropes & Gray LLP

Ropes & Gray LLP

------

## Ex-23

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2021 Equity Incentive Plan and the 2021 Employee Stock Purchase Plan of Cyteir Therapeutics, Inc. of our report dated March 23, 2023, with respect to the consolidated financial statements of Cyteir Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Boston, Massachusetts

March 23, 2023

------

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Tables**

Form S-8

(Form Type)

Cyteir Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security**<br>**Type** | **Security Class Title** | **Fee Calculation**<br>**Rule** | **Amount**<br>**Registered (1)** | **Proposed**<br>**Maximum**<br>**Offering Price Per**<br>**Unit** | **Maximum**<br>**Aggregate**<br>**Offering**<br>**Price** | **Fee Rate** | **Amount of**<br>**Registration**<br>**Fee** |
| Equity | Common Stock, par value $0.001 per share | Other - 457(c) and 457(h) | 1,778,784 shares (2) | $1.65 (4) | $2934993.60 | $110.20 | $323.44 |
| Equity | Common Stock, par value $0.001 per share | Other - 457(c) and 457(h) | 355,756 shares (3) | $1.65 (4) | $586997.40 | $110.20 | $64.68 |
| **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | $3521991.00 |  | $388.12 |
| **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  | $0.00 |
| **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  | $388.12 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this Registration Statement also covers such additional shares of Common Stock as may be issued to prevent dilution from stock splits, stock dividends and similar transactions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Represents an increase to the number of shares available for issuance under the Registrant's 2021 Equity Incentive Plan, effective as of January 1, 2023. Shares available for issuance under the 2021 Plan were previously registered on Form S-8 filed with the Securities and Exchange Commission on July 15, 2021 (Registration No. 333-257920).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)Represents an increase to the number of shares available for issuance under the Registrant's 2021 Employee Stock Purchase Plan, effective as of January 1, 2023. Shares available for issuance under the ESPP Plan were previously registered on Form S-8 filed with the Securities and Exchange Commission on July 15, 2021 (Registration No. 333-257920).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(h) based on the average of the high and low prices of the registrant's Common Stock as reported on the Nasdaq Global Select Market on March 17, 2023 to be $1.71 and $1.59, respectively.

------